Advancing Next-Generation Live Biotherapeutics: Your Partner in Faecalibacterium Research
In the rapidly evolving landscape of the human microbiome, few bacterial genera hold as much promise as Faecalibacterium. As a cornerstone of gut health and a potent producer of butyrate, Faecalibacterium species are at the forefront of the "Next-Generation Probiotic" (NGP) revolution. At our Preclinical Contract Research Organization (CRO), Creative Biolabs specializes in bridging the gap between microbial discovery and clinical application. We provide a comprehensive suite of research services designed to unlock the therapeutic potential of Faecalibacterium spp., supporting biotech and pharmaceutical innovators in developing life-changing Live Biotherapeutic Products (LBPs). From strain isolation and genomic characterization to complex in vivo efficacy models, we are your dedicated partner in navigating the complexities of microbiome-based drug development.
Overview: The Sentinel of the Human Gut
The human gastrointestinal tract is home to trillions of microorganisms, but Faecalibacterium stands out due to its high abundance in healthy individuals and its significant depletion in various disease states. Primarily known for its anti-inflammatory properties, this genus is considered a "sentinel" of intestinal health. Our research services focus on the multifaceted roles these bacteria play in maintaining the mucosal barrier, modulating the immune system, and producing essential short-chain fatty acids (SCFAs).
As a specialized CRO, we understand that Faecalibacterium is notoriously difficult to culture due to its extreme sensitivity to oxygen (it is an extreme obligate anaerobe). Our laboratory is equipped with state-of-the-art anaerobic chambers and specialized cultivation media designed specifically for these fastidious organisms. We provide the technical expertise required to handle these strains safely and effectively, ensuring that your preclinical data is robust, reproducible, and ready for regulatory scrutiny.
Explore Our Specialized Strain Research
To help you navigate the specific therapeutic avenues of different species within this genus, please explore our dedicated research pages below:
As the most well-studied member of the genus, F. prausnitzii is a powerhouse of butyrate production. Research focuses on its ability to secrete anti-inflammatory peptides and its role as a potential biomarker for Inflammatory Bowel Disease (IBD) and metabolic health.
Recently reclassified and distinguished for its unique metabolic profile, F. duncaniae offers new insights into host-microbe interactions. Our research explores its specific ecological niche in the gut and its distinct capabilities in fermenting dietary fibers compared to other family members.
A more recently identified species, F. longum represents the expanding frontier of the genus. Our services include deep genomic sequencing and functional assays to determine how this strain contributes to gut diversity and its potential unique advantages in specific disease models.
Our Preclinical Research Services
Our CRO offers an end-to-end service pipeline tailored to the unique requirements of Live Biotherapeutic development.
We utilize advanced anaerobic techniques to isolate novel Faecalibacterium strains from human donor samples.
Our services include 16S rRNA sequencing and Whole Genome Sequencing (WGS) to ensure precise identification and to screen for antibiotic resistance genes or virulence factors, ensuring safety from the outset.
In accordance with regulatory guidelines for LBPs, we perform safety studies, including acute and repeated-dose toxicity tests in rodents, ensuring that the live bacterial product does not cause adverse systemic effects or translocation.
Products for Research Use
In addition to our service offerings, we provide high-quality standardized products to accelerate your internal R&D:
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Faecalibacterium prausnitzii Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Research Applications: Faecalibacterium in Disease Treatment
The therapeutic application of Faecalibacterium spp. spans a wide array of clinical indications. Because these bacteria interact so closely with the host immune system and the intestinal epithelium, they are being investigated as primary treatments or adjunct therapies for several chronic conditions.
The most significant body of evidence for Faecalibacterium research lies in Crohn's Disease and Ulcerative Colitis. Research has consistently shown that a reduction in Faecalibacterium abundance is a predictor of disease recurrence. The strain works by producing butyrate, which serves as the primary energy source for colonocytes and induces the differentiation of regulatory T-cells (Tregs). Furthermore, it secretes a specific protein known as MAM (Microbial Anti-inflammatory Molecule), which inhibits the NF-κB pathway, thereby reducing pro-inflammatory cytokine production.
Emerging research indicates a strong link between Faecalibacterium levels and metabolic health. Studies suggest that these bacteria can improve insulin sensitivity and reduce systemic low-grade inflammation associated with obesity and Type 2 Diabetes. By strengthening the gut barrier—often referred to as "sealing the leaky gut"—Faecalibacterium prevents the translocation of lipopolysaccharides (LPS) into the bloodstream, which is a major driver of metabolic endotoxemia.
3. The Gut-Brain Axis and Mental Health
The influence of the microbiome extends beyond the gut. There is growing interest in how Faecalibacterium might impact neurological health. By modulating systemic inflammation and producing metabolites that can cross or influence the blood-brain barrier, these strains are being researched for their potential roles in alleviating symptoms of depression, anxiety, and even neurodegenerative diseases.
4. Immuno-Oncology
In the field of cancer research, the presence of certain Faecalibacterium species has been associated with improved responses to immune checkpoint inhibitors (ICIs). Our research services help clients investigate how co-administration of Faecalibacterium-based LBPs can enhance the efficacy of cancer immunotherapies by priming the host's immune system.
Our Advantages as a Leading CRO
Choosing the right partner is critical when dealing with "difficult-to-grow" microbes. Our advantages include:
Deep Domain Expertise
Our team consists of microbiologists and immunologists who have spent decades studying the Ruminococcaceae family.
Cutting-Edge Anaerobic Infrastructure
We operate one of the few facilities capable of high-throughput anaerobic cultivation and screening.
Regulatory Alignment
Our protocols are designed with guidelines for Live Biotherapeutics in mind, facilitating a smoother transition from preclinical to IND filing.
Customizable Research Designs
We don't believe in a one-size-fits-all approach. Every project is tailored to the specific therapeutic goals of our clients.
Partnering for the Future of Gut Health
The potential of Faecalibacterium spp. to transform the treatment of chronic inflammatory and metabolic diseases is immense. However, the path from the laboratory bench to the patient's bedside is fraught with technical challenges. Our mission is to provide the specialized knowledge, advanced technology, and rigorous scientific methodology needed to overcome these hurdles. By choosing our research services, you are ensuring that your Live Biotherapeutic candidates are backed by high-quality preclinical data and a deep understanding of microbial ecology. Together, we can harness the power of the microbiome to usher in a new era of medicine.
Why is Faecalibacterium so difficult to work with compared to Lactobacillus?
Faecalibacterium is an "extreme obligate anaerobe." Even brief exposure to oxygen can be lethal to the cells. This requires specialized equipment and rapid processing techniques that standard microbiology labs often lack.
Can Faecalibacterium be formulated into an oral pill?
Yes, but it requires advanced encapsulation technology to protect the bacteria from stomach acid and oxygen. Our research includes stability testing to help inform these formulation choices.
Is Faecalibacterium considered a "Probiotic"?
While it fits the general definition, in a regulatory context, it is usually classified as a "Live Biotherapeutic Product" (LBP) because it is intended for use as a drug to treat or prevent a specific disease.
Do you work with genetically modified (GM) strains?
Yes, we offer services for the characterization and efficacy testing of engineered Faecalibacterium strains designed to deliver specific therapeutic payloads.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
